DE3920657A1 - New 1-cinnamyl-4-(1-phenyl)-cyclo:hexyl)-piperazine - used to inhibit formation of cardiovascular atheroma - Google Patents

New 1-cinnamyl-4-(1-phenyl)-cyclo:hexyl)-piperazine - used to inhibit formation of cardiovascular atheroma

Info

Publication number
DE3920657A1
DE3920657A1 DE19893920657 DE3920657A DE3920657A1 DE 3920657 A1 DE3920657 A1 DE 3920657A1 DE 19893920657 DE19893920657 DE 19893920657 DE 3920657 A DE3920657 A DE 3920657A DE 3920657 A1 DE3920657 A1 DE 3920657A1
Authority
DE
Germany
Prior art keywords
cinnamyl
piperazine
phenyl
new
atheroma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19893920657
Other languages
German (de)
Inventor
Hans-Joerg Dr Treiber
Eberhard Prof Dr Med Betz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Priority to DE19893920657 priority Critical patent/DE3920657A1/en
Publication of DE3920657A1 publication Critical patent/DE3920657A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cpds. of formula (I) are new. R = 1-phenyl cyclohexyl (a) or 4-cyano-4(3,4,5-trimethoxyphenyl)-5-methyl hexyl (b). I(a) is prepd. by reacting cinnamyl piperazine (IV) with cyclohexanone (V) in an aq. soln. The reaction takes place in the presence of sodium hydrogen sulphite, which is reacted with (V) to form an adduct before adding (IV) and KCN. The resulting 1-cinnamyl-4-(1-cyano)cyclohexyl-piperazine is refluxed with phenyl magnesium bromide and treated with ammonium chloride. USE/ADVANTAGE - To inhibit the formation of atheroma in blood vessels. (I) can be used after angioplasty and heart bypass operations.

Description

Aus der Literatur sind bereits eine große Zahl von Piperazinderivaten bekannt, wobei die bekanntesten Cinnamyl-substituierten Verbindungen, Cinnarizin und Flunarizin, Antihistamin-Eigenschaften, antiarrhythmische und cerebral-durchblutungsfördernde Eigenschaften aufweisen.A large number of are already from the literature Piperazine derivatives are known, the best known Cinnamyl-substituted compounds, cinnarizine and flunarizine, Antihistamine properties, antiarrhythmic and have cerebral circulation-promoting properties.

Zahlreiche andere Piperazine sind mit analgetischer, coronar-vasodilatierender oder blutdrucksenkender Wirkung beschrieben.Numerous other piperazines are analgesic, coronary vasodilating or hypotensive effect described.

Es wurde nun überraschenderweise gefunden, daß Verbindungen der FormelIt has now surprisingly been found that compounds of formula

in der der Rest Rin which the rest R

ist, eine gute antiatherogene Wirkung besitzen.has a good anti-atherogenic effect.

Die Substanzen werden nach bekannten Methoden hergestellt. The substances are manufactured according to known methods.  

Mit den erfindungsgemäßen Verbindungen kann die Bildung von Atheromen in der Gefäßwand und das Fortschreiten bereits bestehender arteriosklerotischer Veränderungen gehemmt bzw. deren Regression gefördert werden.With the compounds according to the invention, the formation of Atheromas in the vascular wall and progression already existing arteriosclerotic changes inhibited or their Regression are encouraged.

Darüber hinaus können die neuen Substanzen auch zur Verhinderung von Restenosierungen und Reobliterationen nach Angioplastien und Bypass-Operationen eingesetzt werden.In addition, the new substances can also be used for prevention of restenosis and reobliterations after angioplasty and Bypass operations are used.

Zum Nachweis ihrer Wirkung werden Massenkulturen und Klonkulturen von SMC und von arteriellen Endothelzellen (EC) mit den neuen Verbindungen in einer Konzentration von 2,2 × 10-5 M inkubiert. Bestimmt wird der Zuwachs an Zellen innerhalb von 9 Tagen bzw. das Wachstum von Klonen aus Einzelzellen innerhalb von 14 Tagen, wobei als Klon eine Gruppe von wenigstens 50 Zellen definiert ist. Als Maß für die Beeinflussung der Proliferation durch die Prüfsubstanzen dient in den Massenkulturen die relative Änderung (%) im Vergleich zu den Kontrollen. Die relative Klonierungseffizienz (RKE) ist die Zahl von Klonen in Kulturschalen mit behandelten Zellen pro Anzahl von Klonen in Kulturschalen der Kontrollgruppe.To demonstrate their effect, mass cultures and clone cultures of SMC and of arterial endothelial cells (EC) are incubated with the new compounds in a concentration of 2.2 × 10 -5 M. The growth of cells within 9 days or the growth of clones from individual cells within 14 days is determined, a group of at least 50 cells being defined as the clone. The measure of the influence of the test substances on proliferation in the mass cultures is the relative change (%) compared to the controls. The relative cloning efficiency (RKE) is the number of clones in culture dishes with treated cells per number of clones in culture dishes of the control group.

Die erfindungsgemäßen Verbindungen hemmen selektiv die Proliferation von SMC in der Massenkultur um jeweils 35% (Tabelle 1) und der Klonkultur um 50% und 64% II (Tabelle 2). Auf die Proliferation von Endothelzellen sind die neuen Substanzen ohne Einfluß (Tabellen 1 und 2). The compounds of the invention selectively inhibit the Proliferation of SMC in the mass culture by 35% each (Table 1) and the clone culture by 50% and 64% II (Table 2). On the proliferation of endothelial cells are the new ones Substances without influence (Tables 1 and 2).  

Tabelle 1 Table 1

Antiatherogene Wirkung Antiatherogenic effect

Einfluß auf die Proliferation von glatten Gefäßmuskelzellen (SMC) und Endothelzellen (EC) Influence on the proliferation of smooth vascular muscle cells (SMC) and endothelial cells (EC)

Tabelle 2 Table 2

Antiatherogene Wirkung Antiatherogenic effect

Einfluß auf die relative Klonierungseffizienz (RKE) Influence on relative cloning efficiency (RKE)

a) Glatte Muskelzellen aus Kaninchenaorten a) Smooth muscle cells from rabbit aorta

b) Endothelzellen aus Rinderaorten b) bovine aortic endothelial cells

BeispieleExamples Beispiel 1Example 1 1-Cinnamyl-4-(1-phenyl)-cyclohexyl)-piperazin (I)1-cinnamyl-4- (1-phenyl) cyclohexyl) piperazine (I)

a) Zu dem aus 9,8 g (0,1 mol) Cyclohexanon und 10 g Natriumhydrogensulfit (in 35 ml Wasser gelöst) hergestellten Addukt fügte man bei 0-5°C innerhalb 20 min 20,2 g (0,1 mol) Cinnamylpiperazin und 6,8 g Kaliumcyanid (in 20 ml Wasser gelöst) und rührte die Mischung 24 h bei Raumtemperatur. Nach weiterem Stehenlassen im Kühlschrank fügte man Wasser zu, schüttelte mit Ether aus und erhielt nach Verdampfen des Ethers 27 g (90% d.Th.) 1-Cinnamyl-4-(1-Cyano)cyclohexyl-piperazin, Fp. 100°C.a) To that from 9.8 g (0.1 mol) of cyclohexanone and 10 g Sodium hydrogen sulfite (dissolved in 35 ml of water) Adduct was added at 0-5 ° C within 20 min 20.2 g (0.1 mol) Cinnamylpiperazine and 6.8 g potassium cyanide (dissolved in 20 ml water) and stirred the mixture at room temperature for 24 hours. After another Leaving it standing in the fridge, water was added, shaken with it Ether and obtained after evaporation of the ether 27 g (90% of theory) 1-cinnamyl-4- (1-cyano) cyclohexyl-piperazine, mp. 100 ° C.

b) Zu 0,3 Mol einer etherischen Lösung von Phenylmagnesiumbromid fügte man portionsweise das zuvor bereitete Aminonitril a) zu; erhitzte 6 h unter Rückfluß, zersetzte die Reaktionsmischung mit Ammoniumchloridlösung und erhielt aus der Etherlösung nach Verdampfen des Ethers die Rohbase, die aus Isopropanol umkristallisiert wurde.b) To 0.3 mol of an ethereal solution of phenylmagnesium bromide the previously prepared aminonitrile a) was added in portions; heated under reflux for 6 h, decomposed the reaction mixture Ammonium chloride solution and received from the ether solution Evaporation of the ether the crude base, which is made of isopropanol was recrystallized.

Fp. 96-97°C, Kp. 0,4 mm 230-240°CMp 96-97 ° C, bp 0.4 mm 230-240 ° C

Mit isopropanolischer Salzsäure erhielt man das Di-Hydrochlorid (Zersetzung) ca. 290°C. The di-hydrochloride was obtained with isopropanolic hydrochloric acid (Decomposition) approx. 290 ° C.  

Beispiel 2Example 2 5-1-(4-E-Cinnamyl)-piperazinyl-2-isopropyl-2-(3,4,5-trimethoxyphenyl-)valeronitril (II)5-1- (4-E-cinnamyl) piperazinyl-2-isopropyl-2- (3,4,5-trimethoxyphenyl) valeronitrile (II)

62,5 g (0,19 mcl) -Isopropyl-(3-chlorpropyl)-3,4,5-trimethoxyphenylacetonitril und 85 g (0,42 mol) 1-(E)-Cinnamylpiperazin wurde in 100 ml N,N′-Dimethylethylenharnstoff 4 Stunden auf 70°C erwärmt. Nach dem Erkalten wurde mit 500 ml Ether verdünnt und das ausgefallene 1-(E)-Cinnamylpiperazin-dihydrochlorid abgesaugt. Die Etherphase wurde zur Entfernung von überschüssiger Ausgangsbase mit 25 ml 10%iger Salzsäure extrahiert und anschließend noch zweimal mit Wasser gewaschen. Nach Trocknen und Abziehen des Ethers wurde der ölige Rückstand in 500 ml Isopropanol aufgenommen und zur Ausfällung des Dihydrochlorids mit isopropanolischer Salzsäure versetzt. Nach Umkristallisation aus Isopropanol unter Zusatz von 1% Wasser isolierte man 90 g (83% d. Th.) Dihydrochlorid, Fp. 223-225°C.62.5 g (0.19 mcl) isopropyl (3-chloropropyl) -3,4,5-trimethoxyphenylacetonitrile and 85 g (0.42 mol) of 1- (E) -cinnamylpiperazine was in 100 ml N, N'-Dimethylethylene urea heated to 70 ° C for 4 hours. To the cooling was diluted with 500 ml of ether and the precipitated Aspirated 1- (E) -cinnamylpiperazine dihydrochloride. The ether phase was used to remove excess starting base with 25 ml 10% hydrochloric acid extracted and then twice with Washed water. After drying and stripping the ether, the oily residue taken up in 500 ml of isopropanol and Precipitation of the dihydrochloride with isopropanolic hydrochloric acid transferred. After recrystallization from isopropanol with the addition of 1% water isolated 90 g (83% of theory) of dihydrochloride, Mp 223-225 ° C.

Claims (1)

Verbindungen der Formel in der der Rest R ist.Compounds of the formula in which the rest R is.
DE19893920657 1989-06-23 1989-06-23 New 1-cinnamyl-4-(1-phenyl)-cyclo:hexyl)-piperazine - used to inhibit formation of cardiovascular atheroma Withdrawn DE3920657A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19893920657 DE3920657A1 (en) 1989-06-23 1989-06-23 New 1-cinnamyl-4-(1-phenyl)-cyclo:hexyl)-piperazine - used to inhibit formation of cardiovascular atheroma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19893920657 DE3920657A1 (en) 1989-06-23 1989-06-23 New 1-cinnamyl-4-(1-phenyl)-cyclo:hexyl)-piperazine - used to inhibit formation of cardiovascular atheroma

Publications (1)

Publication Number Publication Date
DE3920657A1 true DE3920657A1 (en) 1991-01-10

Family

ID=6383450

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19893920657 Withdrawn DE3920657A1 (en) 1989-06-23 1989-06-23 New 1-cinnamyl-4-(1-phenyl)-cyclo:hexyl)-piperazine - used to inhibit formation of cardiovascular atheroma

Country Status (1)

Country Link
DE (1) DE3920657A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2364669A3 (en) * 1998-09-10 2012-03-14 JenaValve Technology Inc. Transmyocardial shunt
US10993805B2 (en) 2008-02-26 2021-05-04 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11065138B2 (en) 2016-05-13 2021-07-20 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
US11185405B2 (en) 2013-08-30 2021-11-30 Jenavalve Technology, Inc. Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
US11197754B2 (en) 2017-01-27 2021-12-14 Jenavalve Technology, Inc. Heart valve mimicry
US11337800B2 (en) 2015-05-01 2022-05-24 Jenavalve Technology, Inc. Device and method with reduced pacemaker rate in heart valve replacement
US11357624B2 (en) 2007-04-13 2022-06-14 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
US11517431B2 (en) 2005-01-20 2022-12-06 Jenavalve Technology, Inc. Catheter system for implantation of prosthetic heart valves
US11564794B2 (en) 2008-02-26 2023-01-31 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11589981B2 (en) 2010-05-25 2023-02-28 Jenavalve Technology, Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2364669A3 (en) * 1998-09-10 2012-03-14 JenaValve Technology Inc. Transmyocardial shunt
US11517431B2 (en) 2005-01-20 2022-12-06 Jenavalve Technology, Inc. Catheter system for implantation of prosthetic heart valves
US11357624B2 (en) 2007-04-13 2022-06-14 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
US10993805B2 (en) 2008-02-26 2021-05-04 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11154398B2 (en) 2008-02-26 2021-10-26 JenaValve Technology. Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11564794B2 (en) 2008-02-26 2023-01-31 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11589981B2 (en) 2010-05-25 2023-02-28 Jenavalve Technology, Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
US11185405B2 (en) 2013-08-30 2021-11-30 Jenavalve Technology, Inc. Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
US11337800B2 (en) 2015-05-01 2022-05-24 Jenavalve Technology, Inc. Device and method with reduced pacemaker rate in heart valve replacement
US11065138B2 (en) 2016-05-13 2021-07-20 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
US11197754B2 (en) 2017-01-27 2021-12-14 Jenavalve Technology, Inc. Heart valve mimicry

Similar Documents

Publication Publication Date Title
DE1695160A1 (en) Process for the preparation of a cytosine compound
DE3920657A1 (en) New 1-cinnamyl-4-(1-phenyl)-cyclo:hexyl)-piperazine - used to inhibit formation of cardiovascular atheroma
DE2106694C2 (en) Phthalimidine derivatives, process for their preparation and their use
US4731376A (en) 2-(-(2,2,5,5-tetramethyl-3-pyrrolin-3-carbonyl))-amino derivatives
DE1518452A1 (en) Process for the preparation of 4-substituted 2-benzhydryl-2-butanol derivatives
DE1620016B2 (en) 3- (Piperazinoalkyl) pyrazoles and processes for their preparation
DE2236423A1 (en) AMINOPROPANOL DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND THEIR USE IN HUMAN MEDICINE
CH642365A5 (en) METHOD FOR PRODUCING 6-PIPERIDINO-2,4-DIAMINOPYRIMIDIN-3-OXIDE.
US2971955A (en) Cyclohexylcarbinol derivatives of piperazine
DE3220185A1 (en) 4-AMINO-BENZYLAMINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS PHARMACEUTICALS
AT211316B (en) Process for the preparation of new phenthiazine compounds
AT257588B (en) Process for the preparation of new 4- (piperazinoalkyl) pyrazoles and their acid addition salts
AT334902B (en) PROCESS FOR THE PREPARATION OF NEW 1,4-DIHYDROPYRIDINE-3-CARBONONIC ACID AMINO ALKYLESTER AND THEIR ACID ADDITION SALTS
DE737931C (en) Process for the preparation of 2,4-diaminochinazoline
AT236381B (en) Process for the preparation of new piperazine compounds
AT303732B (en) PROCESS FOR THE PRODUCTION OF PHENYLBUTAN-1-OLEN AND OF ACID ADDITION SALT OF THESE COMPOUNDS
AT233570B (en) Process for the preparation of new N-phenylpiperazine derivatives
AT235284B (en) Process for the production of new indole derivatives
DE1795619A1 (en) Process for the preparation of 1,3-disubstituted 4- (2-aminoaethyl) -2-imidazolidinones
AT213884B (en) Process for the preparation of new 3-phenyl-3-pyrrolidinol compounds
AT222110B (en) Process for the preparation of 4-chloro-3-sulfamylbenzamides
AT360017B (en) METHOD FOR PRODUCING THE NEW 1-METHYL-4- (3-CARBOXY-10,11-DIHYDRO-5H-DIBENZO- (A, D) - -CYCLOHEPTEN-5-YLIDEN) -PIPERIDINE (10,11-DIHYDRO -3- CARBOXY-CYPROHEPTADINE), HIS N-OXIDS AND HIS SALTS
CH509992A (en) Process for the preparation of sulfonamides
DE1445142C3 (en) 2- (Benzolsurfonamido) -5-methoxyethoxypyrimidine derivatives
AT242137B (en) Process for the preparation of new derivatives of 4-aminobutyn- (2, 3) -ol-1 and their salts

Legal Events

Date Code Title Description
8130 Withdrawal